Overall medical encounters in patients with T2DM and TUD
(Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
5,954	semaglutide	insulins	5,869 (98.6%)	5,654 (95.0%)	3.6% (3.0%, 4.2%)		0.81 (0.78–0.84)
5,955	semaglutide	metformin	5,870 (98.6%)	5,773 (96.9%)	1.6% (1.1%, 2.2%)		1.08 (1.04–1.12)
4,831	semaglutide	DPP–4i	4,755 (98.4%)	4,636 (96.0%)	2.5% (1.8%, 3.1%)		1.12 (1.07–1.16)
5,325	semaglutide	SGLT2i	5,244 (98.5%)	5,152 (96.8%)	1.7% (1.1%, 2.3%)		1.10 (1.06–1.14)
5,388	semaglutide	SU	5,309 (98.5%)	5,152 (95.6%)	2.9% (2.3%, 3.5%)		1.13 (1.09–1.17)
2,659	semaglutide	TZD	2,603 (97.9%)	2,495 (93.8%)	4.1% (3.0%, 5.1%)		1.15 (1.09–1.22)
5,337	semaglutide	other GLP–1RAs	5,258 (98.5%)	5.124 (96.1%)	2.5% (1.9%, 3.1%)		1.11 (1.07–1.15)

0.30 0.40   0.60 0.80 1.0   2.0   3.00

Hazard Ratio (HR)